WO1997044810A1 - Method of improving skin condition - Google Patents

Method of improving skin condition Download PDF

Info

Publication number
WO1997044810A1
WO1997044810A1 PCT/US1997/007936 US9707936W WO9744810A1 WO 1997044810 A1 WO1997044810 A1 WO 1997044810A1 US 9707936 W US9707936 W US 9707936W WO 9744810 A1 WO9744810 A1 WO 9744810A1
Authority
WO
WIPO (PCT)
Prior art keywords
substrate
wekroma
potential field
magnetic vector
vector potential
Prior art date
Application number
PCT/US1997/007936
Other languages
English (en)
French (fr)
Inventor
Joseph Gubernick
Gheorghe Cioca
Original Assignee
E-L Management Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by E-L Management Corporation filed Critical E-L Management Corporation
Priority to AU30028/97A priority Critical patent/AU708049B2/en
Priority to CA002256348A priority patent/CA2256348C/en
Priority to IL12718297A priority patent/IL127182A0/xx
Priority to JP54246197A priority patent/JP2001508761A/ja
Publication of WO1997044810A1 publication Critical patent/WO1997044810A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N2/00—Magnetotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/83—Electrophoresis; Electrodes; Electrolytic phenomena
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/87—Application Devices; Containers; Packaging

Definitions

  • the present invention relates to the field of homeopathic treatments, and more particularly, to the use of a physiologically acceptable substrate containing information energy for cosmetic and medical applications.
  • Homeopathy has been explained as copying information, e .g. , a pattern or a combination of oscillations of different frequencies, onto a substrate from the information or pattern existing in the molecular structure of natural substances, e .g. , herbs, antibodies, or pollen.
  • the substrate with the copied information or pattern incorporated therein can then be used to effect a desired response.
  • the desired response might be the reduction of allergy symptoms in hay fever sufferers.
  • K. E. Werner Kropp teaches a process for the manufacture of a synthetic homeopathic substrate by placing the substrate between opposing sets of magnets.
  • An object of the present invention is to provide a novel method of using physiologically acceptable substrates containing information energy for use in cosmetics, e . g. . for improving skin condition. . . .
  • Another object of the present invention is to provide a novel method of using physiologically acceptable substrates containing information energy for use in homeopathic medicine.
  • the invention is related to the use of substrates such as aqueous salt solutions, massage oils or other pharmaceutically acceptable carriers that have been exposed to information energy such as oscillation patterns modeled after those found in natural herbs.
  • the substrate can be in the gaseous, liquid, solid or liquid crystalline phase.
  • the aqueous salt solutions may contain sodium chloride and magnesium chloride, as well as dissolved iron and calcium ions.
  • the substrates that contain information energy can be used to improve skin condition by topically administering the substrates to skin.
  • skin condition we mean, without limitations, dry skin, zerosis, ichthyosis, dandruff, brownish spots, keratoses, melasma, lentigines, age spots, liver spots, pigmented spots, wrinkles, blemishes, skin lines, oily skin, acne, warts, eczema, pruritic skin, psoriasis, inflammatory dermatoses, disturbed keratxnxzation , skin changes associated with aging, nail or skin requiring cleansers, conditioning or treatment, and hair or scalp requiring shampooing or conditioning.
  • the present invention provides a specific method of increasing proline uptake in human dermal fibroblast cells by contacting the cells with a physiologically acceptable substrate that contains information energy.
  • Increased proline uptake is an indication of the collagen synthesis of these cells - - a desirable cosmetic benefit which is one route of improving skin condition.
  • Fibroblast cells which are located in the dermis, perform many functions, i.e., synthesize collagen, elastin, glycoseaminoglycans (GAGS) , to name a few.
  • Proline is an amino acid which is an integral part of the collagen structure.
  • Collagen and elastin are two proteins found in the dermis responsible for the firmness and elasticity of the skin. Young, healthy skin has an abundance of these two proteins. As the body ages, the process of synthesizing these proteins decreases. Therefore, the total amount of collagen/elastin diminishes in older, less healthy skin. Increasing the amount of collagen/elastin in the dermis by the present invention leads to improvement in skin condition.
  • the present invention further provides a specific method of producing the physiologically acceptable substrate that contains information energy.
  • the method is generally described in U.S. Patents 5,012,110 and 5,138,172 of K. E.
  • Werner Kropp comprises imparting information energy of desired frequencies to a substrate that has been placed in a specific configuration within a magnetic field, called a magnetic vector potential field.
  • the apparatus for applying the information energy to the substrate may comprise a) two opposite sets of magnets, each said set of magnets comprising a plurality of magnets arranged side by side, with alternating N and
  • the application of information energy to the substrate may be accomplished by exposing the substrate to the following Wekroma rods having the following properties:
  • Fibro 2 Stimulate fibroblast cells Preferably, the substrate is exposed to the above Wekroma Rods by the use of a Wekroma Bio-Transer device, wherein the substrate is at least once passed through such device.
  • the substrate may be exposed to the rods individually or in combination.
  • the present invention additionally provides a method of improving skin condition comprising a) exposing a physiologically acceptable substrate to a magnetic vector potential field; and b) administering to the skin the exposed substrate.
  • a substrate to a magnetic vector potential field, such as the sets of magnets described above without application of information energy is sufficient to obtain a treated substrate capable of improving skin condition.
  • One preferable way of treating the substrate with a magnetic vector potential field is to pass the substrate at least once through the Wekroma Bio-Transer device, without the placement of any Wekroma Rods within the device.
  • FIG. 1 depicts the Bio-Transer device available from Wekroma-Vertrieb für.
  • Fig. 2 depicts graphically the increase in proline level in Human Dermal Fibroblast cells upon increasing the concentration of the Body Booster mineral water that was treated with the Wekroma Bio-Transer device.
  • the substrate is generally in a gaseous, liquid, solid or liquid crystalline phase.
  • Step 2 The solution obtained in Step 1 was split into 5 equal aliquots and stored in sterile test tubes.
  • Sample No. 1 was left untreated; to be used as a control to compare to the other treated samples.
  • Rod No. 232-1 (as supplied by Wekroma) was placed in the
  • test tubes containing the sterile salt solution was then passed through the Bio-Transer as depicted in the accompanying drawing. This procedure was repeated two times. Then the sample was set aside.
  • Rod No. 232-1 was removed from the Bio-Transer and Rod No. 232-2 was placed in the Bio-Transer.
  • Another of the test tubes containing the sterile salt solution was passed through the Bio-Transer as in Step No. 5.
  • Rods No. 232-1, 2, 3 and 4 are identical replicas of each other.
  • the protocol for the proline uptake testing is as follows. Two confluent 24-well plates were treated with the sample solutions. The untreated salt solution control was added neat in 1, 5, and 10% concentrations. Solutions of the same material was passed through Rod No. 232 and assayed at the same concentrations as the control. Each sample was assayed in triplicate. The samples were then labeled with l ⁇ Ci/ml of 3 H Proline by adding 1 ⁇ l to each ml well. Plates were incubated over a five day period, in which time the treatment procedure was repeated. After treatment incubation was complete, the plates were assayed for total protein uptake.
  • Body Booster mineral water having the composition listed in Table 1 was treated in a Wekroma Bio-Transer device using
  • Each sample was assayed in triplicate using . l, .5 and 1% concentrations. Plates were incubated over the weekend before being assayed for total protein. At this time each plate was washed with 1 ml of ice cold PBS, and then l ml of ice cold TCA for 10 minutes. TCA washes were repeated twice for five minutes each. Each plate was then washed with 1 ml of MeOH and allowed to dry. Protein was then solubilized in .3 M NaOH containing 1% SDS and gently shaken for .5 hours.
  • Rod No. 232 as outlined in Example 1 resulted in higher proline uptake compared to the untreated mineral water control. Treatment of this mineral water with the Wekroma
  • Booster control was added neat in 1, 5, and 10% concentrations. The same material was passed through Rods
  • Each sample was assayed in triplicate. The samples were then labeled with 1 ⁇ Ci/ml of 3 H Proline by adding 1 ⁇ l to each ml well. Plates were incubated over a five day period, in which time the treatment procedure was repeated. After treatment incubation was complete, the plates were assayed for total protein uptake. Each plate was washed with 1 ml of ice cold
  • Protein was then solubilized in .3 M NaOH and gently shaken for .5 hours. Supernatant is collected and added to scintillant, and measured on the liquid scintillation counter.
  • Body Booster increased uptake 52% when treated with Rods 232, yielding a 12% increase from the untreated group, while 1200.7 treatment paralleled the untreated group. Student's t-test indicated that all the materials were statistically significant. See Table 3.
  • Body Booster mineral water increased uptake 44, 38, and 33% as a control at 1, 5, and 10% concentrations.
  • Body Booster mineral water treated with Rods No. 1200.7 (antioxidant) 5 displayed increases of 6 and 16% at 5 and 10% concentrations respectively, when compared to Body Booster mineral water controls.
  • Student's t-test conveyed statistical significance _ for all materials, when values were compared to untreated controls.
  • Statistical analysis compared to Body Booster mineral water control, yielded values greater than .05 excluding the 10% concentration that had been treated with 5 Rod No. 1200.7
  • NHDF Dermal Fibroblasts cells
  • ⁇ NHDF cells were seeded and grown to confluence in a 96 well plate prior to being treated with the Wekroma samples
  • Mimosa pudica (@ 50 ⁇ g/ml) was added as a positive control and media alone served as the negative control. The plate was incubated for 4 days at 37°C/5% C0 2 before the supernatants were harvested, and stored at -70° in siliconized tubes until the ELISA was performed.
  • the collagen ELISA was performed as follows: A 96 well enzyme immunoassay grade microliter plate is coated, overnight at 4°C, with an optimal amount of Human
  • Type 1 collagen In a separate microliter plate (low protein binding) , equal volumes of primary antibody (Rabbit anti
  • Human Type l Collagen Human Type l Collagen is mixed with either the collagen standards or the unknowns and allowed to react overnight at
  • the collagen coated plate is then washed extensively with Phosphate Buffered Saline containing 0.05% Tween-20
  • the blocking solution is then removed from the wells, the plate is dried and the contents of the wells containing the primary antibody/standard or unknown solution are transferred to the blocked, collagen coated plate.
  • the plate is incubated for 30 minutes at room temperature, to allow whatever primary anti-body is left unbound to free collagen, to bind to the collagen coating the plate. After the 30 mi.nute i.ncubati.on, the solution is discarded. Discarded in the solution will be the primary antibody bound to free collagen (from the standards or unknowns) . Any primary antibody that did not bind to collagen during the inhibition step will be free to bind to the collagen coating the wells.
  • the primary antibody bound to the collagen coating the well is detected by the addition of a goat anti-rabbit lgG-
  • DNA assay was performed as follows. DNA levels are determined by performing a freeze/thaw lysis of the cells in the presence of water and adding Hoechst 33258 (a dye that binds to DNA and becomes fluorescent) . The plate is then read on the spectrophotometer and DNA levels are calculated from the standard curve.
  • Hoechst 33258 a dye that binds to DNA and becomes fluorescent
  • Such a treated substrate is capable of improving skin condition upon administration of the substrate to the skin.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Dermatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Birds (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Apparatuses For Bulk Treatment Of Fruits And Vegetables And Apparatuses For Preparing Feeds (AREA)
  • Fats And Perfumes (AREA)
  • Lasers (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PCT/US1997/007936 1996-05-21 1997-05-13 Method of improving skin condition WO1997044810A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU30028/97A AU708049B2 (en) 1996-05-21 1997-05-13 Method of improving skin condition
CA002256348A CA2256348C (en) 1996-05-21 1997-05-13 Method of improving skin condition
IL12718297A IL127182A0 (en) 1996-05-21 1997-05-13 Method of improving skin condition
JP54246197A JP2001508761A (ja) 1996-05-21 1997-05-13 皮膚コンディションの改善方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/646,798 1996-05-21
US08/646,798 US5905265A (en) 1996-05-21 1996-05-21 Method of improving skin condition

Publications (1)

Publication Number Publication Date
WO1997044810A1 true WO1997044810A1 (en) 1997-11-27

Family

ID=24594498

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/007936 WO1997044810A1 (en) 1996-05-21 1997-05-13 Method of improving skin condition

Country Status (13)

Country Link
US (1) US5905265A (forum.php)
JP (1) JP2001508761A (forum.php)
KR (1) KR100450713B1 (forum.php)
CN (1) CN1123050C (forum.php)
AR (1) AR048562A1 (forum.php)
AU (1) AU708049B2 (forum.php)
CA (1) CA2256348C (forum.php)
CO (1) CO4850561A1 (forum.php)
IL (1) IL127182A0 (forum.php)
IN (1) IN183686B (forum.php)
TW (2) TW483020B (forum.php)
WO (1) WO1997044810A1 (forum.php)
ZA (1) ZA974421B (forum.php)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6652747B2 (en) 1998-07-27 2003-11-25 John Nikolaj Hvarre Device and a method for the treatment of tap water and drinking water
GR20030100201A (el) * 2003-05-07 2005-01-25 Evalionαανωνυμηαεταιρειααπαροχησαυπηρεσιων-Συμβουλευτικη-Εμπορικηαα Μεθοδοσαμεταφορασασυχνοτητωνασεαουσιεσαμεσωακρυσταλλωνακαιαπαρασκευηασκευασματωνατααοποιααπεριεχουνατισασυχνοτητεσααυτεσαα

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6290993B1 (en) * 1999-07-23 2001-09-18 E-L Management Corp. Compositions containing mimosa phenolic compounds
JP2003137807A (ja) * 2001-11-01 2003-05-14 Miyagi Kagaku Kogyo Kk コラーゲン産生促進剤、それを含む化粧品、食品および医薬品ならびに皮膚疾患の予防または改善用外用剤
DE10223221A1 (de) * 2002-05-24 2003-12-11 Sebapharma Gmbh & Co Kg Kosmetische Zusammensetzung mit hautentquellender Wirkung
JP2004167467A (ja) * 2002-11-15 2004-06-17 Lidic Inc 振動情報記録水
JP2004337831A (ja) * 2003-05-16 2004-12-02 Lidic Inc 生体の生命力を支援する振動情報の生成方法
JP4916143B2 (ja) * 2005-08-04 2012-04-11 サッポロビール株式会社 ビール酵母で発酵させたアルコール飲料からコラーゲン産生促進作用を有する組成物を製造する方法及びその組成物
US20100181261A1 (en) * 2009-01-22 2010-07-22 Eagle Research LLC Aqueous environment treatment apparatus and method

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5012110A (en) * 1986-04-11 1991-04-30 Kropp Werner Substrate and process and apparatus for the production therefor
US5247179A (en) * 1990-10-18 1993-09-21 Hiroshi Tachibana Activation energy providing device

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0538361A4 (en) * 1990-07-06 1993-05-19 Iit Research Institute Method and apparatus for rendering medical materials safe

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5012110A (en) * 1986-04-11 1991-04-30 Kropp Werner Substrate and process and apparatus for the production therefor
US5138172A (en) * 1986-04-11 1992-08-11 Kropp Werner Apparatus and method for applying information energy to a substrate
US5247179A (en) * 1990-10-18 1993-09-21 Hiroshi Tachibana Activation energy providing device

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6652747B2 (en) 1998-07-27 2003-11-25 John Nikolaj Hvarre Device and a method for the treatment of tap water and drinking water
GR20030100201A (el) * 2003-05-07 2005-01-25 Evalionαανωνυμηαεταιρειααπαροχησαυπηρεσιων-Συμβουλευτικη-Εμπορικηαα Μεθοδοσαμεταφορασασυχνοτητωνασεαουσιεσαμεσωακρυσταλλωνακαιαπαρασκευηασκευασματωνατααοποιααπεριεχουνατισασυχνοτητεσααυτεσαα

Also Published As

Publication number Publication date
CA2256348A1 (en) 1997-11-27
AU708049B2 (en) 1999-07-29
IL127182A0 (en) 1999-09-22
US5905265A (en) 1999-05-18
CN1226338A (zh) 1999-08-18
IN183686B (forum.php) 2000-03-18
CO4850561A1 (es) 1999-10-26
KR100450713B1 (ko) 2004-12-03
AR048562A1 (es) 2006-05-10
CA2256348C (en) 2002-07-23
TWI272635B (en) 2007-02-01
KR20000011142A (ko) 2000-02-25
TW483020B (en) 2002-04-11
AU3002897A (en) 1997-12-09
CN1123050C (zh) 2003-10-01
JP2001508761A (ja) 2001-07-03
ZA974421B (en) 1997-12-22

Similar Documents

Publication Publication Date Title
Rudman et al. Bile acid content of human serum. II. The binding of cholanic acids by human plasma proteins
Seegers et al. Inhibition of autoprothrombin C activity with plasma
EP1896497B1 (de) Verfahren zur diagnose von rheumatischen erkrankungen
Medrano et al. Effect of colchicine, vinblastine and cytochalasin B on human lymphocyte transformation by phytohemagglutinin
AU708049B2 (en) Method of improving skin condition
Dalmasso et al. Interaction of Autologous Complement with Red Cells in the Absence of Antibody.
Hardy et al. PROTEINS IN MULTIPLE MYELOMA INTERACTION WITH METABOLIC NITROGEN
Bahnak et al. Effects of alloxan diabetes on the turnover of rat liver glycogen synthase. Comparison with liver phosphorylase.
Murphy et al. Erythrocyte microtubule assembly in vitro. Determination of the effects of erythrocyte tau, tubulin isoforms, and tubulin oligomers on erythrocyte tubulin assembly, and comparison with brain microtubule assembly.
Miyachi et al. Biochemical demonstration and immunohistochemical localization of calpain in human skin
Keiser et al. Collagen-like protein in human plasma
Strunk et al. Human peripheral blood monocyte-derived macrophages produce haemolytically active C3 in vitro
Pearson et al. Studies of ferritin and a new iron-binding protein found in the intestinal mucosa of the rat
Ødum et al. Human inter-α-trypsin inhibitor and immunologically related inhibitors investigated by quantitative immunoelectrophoresis. II. Pathological conditions
Riser et al. Gadolinium-induced fibrosis is counter-regulated by CCN3 in human dermal fibroblasts: a model for potential treatment of nephrogenic systemic fibrosis
Anuradha et al. An isolectin complex from Trichosanthes anguina seeds
Resnick et al. Calcium-binding proteins and renal lithiasis
JPH06508111A (ja) 甲状腺由来の軟骨細胞刺激因子
Orozco et al. A description of the basic system of components in pregnant mice sera responsible for'early pregnancy factor'activity
Schultz et al. Cyanate as an inactivator of complement proteins
RU2195665C2 (ru) Способ определения ингибирующего действия веществ на комплемент
Lajtha et al. Dynamics of protein metabolism in the nervous system
Ito et al. Immunohistochemical study of utrophin and dystrophin at the motor end-plate in myasthenia gravis
Nibbelink et al. Plasminogen depletion during administration of epsilon-aminocaproic acid
Shearer et al. Anti-rabbit thymus actin antibody inhibits proliferation of Epstein-Barr virus-transformed human B cell line LA350: Augmentation by cyclic AMP

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 97196632.X

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AU AZ BA BB BG BR BY CA CN CU CZ EE GE GH HU IL IS JP KG KP KR KZ LC LK LR LT LV MD MG MK MN MX NO NZ PL RO RU SG SI SK TJ TM TR TT UA UZ VN YU AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1019980709302

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2256348

Country of ref document: CA

Ref document number: 2256348

Country of ref document: CA

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 1997 542461

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref document number: 97542461

Country of ref document: JP

NENP Non-entry into the national phase

Ref document number: 97542461

Country of ref document: JP

NENP Non-entry into the national phase

Ref document number: 1997542461

Country of ref document: JP

122 Ep: pct application non-entry in european phase
WWP Wipo information: published in national office

Ref document number: 1019980709302

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 1019980709302

Country of ref document: KR